

Aus der Chirurgische Klinik  
der Medizinischen Fakultät Mannheim  
(Direktor: Prof. Dr. med. Post)

**The use of optical assays in the development of receptor kinase  
specific antitumor therapy**

Inauguraldissertation  
zur Erlangung des Doctor scientiarum humanarum (Dr.sc.hum)  
der  
Medizinischen Fakultät Mannheim  
der Ruprecht-Karls-Universität  
zu  
Heidelberg

vorgelegt von  
Zhala Ahmadova  
  
aus  
Baku, Aserbaidtschan  
2014

Tag der mündlichen Prüfung:

- 9. JUNI 2015

## TABLE OF CONTENTS

	Pages
<b>LIST OF FIGURES</b> .....	<b>6</b>
<b>ABBREVIATIONS</b> .....	<b>7</b>
<b>1. INTRODUCTION</b> .....	<b>9</b>
1.1. Importance of angiogenesis .....	9
1.2. The Vascular Endothelial Growth Factor (VEGF) family ligands and receptors ...	9
1.2.1. Biological and functional characteristics of VEGF ligands .....	10
1.2.2. Vascular endothelial growth factor receptors (VEGFRs).....	11
1.3. Mechanism of VEGFR activation.....	13
1.3.1. Signaling properties of VEGF and VEGFRs in cancer.....	16
1.4. Epidermal Growth Factor Receptor (EGFR).....	17
1.4.1. EGFR signaling in cancer .....	17
1.5. Targeted therapy in cancer .....	18
1.5.1. Inhibition of VEGF pathways and their limitations.....	19
1.5.2. VEGFR2 dimerization: a more specific target in the angiogenic process?.....	21
1.5.3. Inhibition of EGFR signalling .....	22
1.5.4. A model of targeted treatment for colorectal cancer .....	23
1.6. Aims of the thesis.....	24
<b>2. MATERIALS AND METHODS</b> .....	<b>25</b>
2.1. Materials and equipment .....	25
2.1.1. Chemicals and kits.....	25
2.1.2. Enzymes.....	25
2.1.3. Reagents and buffers .....	25
2.1.4. DNA primers and oligonucleotides.....	25
2.1.5. Plasmids .....	26
2.1.6. DNA sequencing.....	26
2.1.7. Bacteria .....	26
2.1.8. Cell culture.....	26
2.1.9. Cell lines .....	27
2.1.10. Growth factors and drugs .....	27
2.1.11. Inhibitors .....	27
2.1.12. Antibodies.....	27
2.1.13. Microscopes and other equipment.....	28
2.1.14. Software .....	28
2.2. Methods .....	29
2.2.1. Vector design.....	29
2.2.2. Cell culture techniques .....	33

## TABLE OF CONTENTS

2.2.3. Data acquisition and analysis .....	35
2.2.4. Statistics .....	43
<b>3. RESULTS .....</b>	<b>44</b>
3.1. VEGFRs show membrane and perinuclear localization .....	44
3.2. VEGFRs form homodimers and heterodimers .....	46
3.3. Conformation of VEGFRs homo- and heterodimerization .....	48
3.3.1. FRET controls .....	48
3.3.2. FRET imaging of VEGF-induced VEGFR dimerization.....	53
3.4. VEGFR dimer formation correlates with VEGF stimulation dose- and time.....	56
3.4.1. VEGFR1 and VEGFR2 heterodimers exist in a pre-assembled form.....	57
3.5. AG1478 is a highly potent inhibitor of EGFR phosphorylation.....	58
3.6. FRET confirms inhibitory effect of AG1478 on EGFR phosphorylation. ....	59
3.7. AG1478 inhibits cell proliferation more potently than 5-FU .....	60
3.8. Apoptosis induction by AG1478 .....	61
<b>4. DISCUSSION.....</b>	<b>62</b>
4.1. Monitoring of dimerization .....	62
4.2. VEGFR1 homodimers and VEGFR1/2 heterodimers show distinct responses to VEGF binding. ....	64
4.3. Impairing tumor angiogenesis via inhibition of VEGFR2 dimer formation.....	66
4.4. Targeted treatment of colorectal cancer.....	67
4.5. Combination of the EGFR tyrosine kinase inhibitor AG1478 and 5-FU shows no synergistic effect.....	68
<b>5. SUMMARY.....</b>	<b>70</b>
<b>6. BIBLIOGRAPHY.....</b>	<b>72</b>
<b>7. CURRICULUM VITAE .....</b>	<b>86</b>
<b>8. PUBLICATIONS .....</b>	<b>87</b>
<b>9. ACKNOWLEDGEMENTS.....</b>	<b>88</b>